IMI 10th anniversary scientific symposium in October 2018Start Date 22/10/2018 End Date 23/10/2018
IMI was launched in 2008 as a public-private partnership (PPP) between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Since then, we have launched almost 100 projects, all of which take a collaborative, open innovation approach to some of the biggest challenges in medical research and drug development today, such as severe asthma, Alzheimer’s disease, diabetes and cancer, to name but a few.
As IMI approaches its 10th anniversary, we have a chance to step back and reflect on 10 years of activity that has resulted in some amazing things happening thanks to the sterling work carried out in our projects.
The time has come to bring our project partners together to share with the wider scientific community their high-quality research, and to provide a space for projects to learn from one another. We hope that this discussions will trigger new ideas, bringing the research funded by IMI a step further.
This is why we are organising IMI's first Scientific Symposium on 22 and 23 October 2018 in Brussels.
The scientific programme will cover four areas in four half-day sessions, reflecting the particular advantages of conducting research in PPP consortia:
- New targets, tools and pathways: this area will include new discoveries and the development of new tools and biomarkers, which have supported disease taxonomies and patient stratification approaches, monitored disease progression, provided proof of pharmacological response, predicted and monitored the efficacy and safety of drugs and vaccines.
- From concept to trial: in this section we will look at how new research findings can be translated to the clinic and how, through collaboration, this phase can be accelerated.
- New clinical and regulatory paradigms: the whole area of personalised medicine is driving the need to look at different ways of designing and conducting clinical trials for evidence generation and innovative approaches in regulatory marketing authorisation processes and HTA/payer access decision-making.
- Patient engagement along the value chain: the voice of the patient continues to be a critical factor in making progress and exploring new ways of looking at medical innovation. This includes incorporating patients’ perspective in the medicinal product lifecycle (from development to regulatory approval and patients’ access), educating new generations of patients, and integrating patient’s ideas in co-developing new ideas for innovation in the health sector.
By looking at past achievements, we want also to look to the future and discuss IMI’s contribution to the preparation of the next generation of scientists and innovators. In order to highlight their journey within IMI projects, both oral and poster presentations will be open only to young researchers.
We cordially invite IMI projects to submit an abstract to one or more of the areas covered by the scientific programme through the online form.
We advise you to read the accompanying abstract submission instructions for authors before filling in the form.
Note: Some users are currently experiencing difficulty submitting abstracts through our system. If this happens to you, you may send your submission in Word to IMI_Events[AT]imi.europa.eu. We apologise for any inconvenience this may cause.
Abstract submission opens: 13 December 2017
Deadline abstract submission: 07 April 2018
Have questions? Please read our list of questions and answers
Meet the Programme Committee
Abstracts will be reviewed by a Programme Committee made up of leading scientists from a range of fields. The committee is chaired by Professor Michel Goldman.
- Professor Michel Goldman, Institute for Interdisciplinary Innovation in Healthcare (I³h), Université Libre de Bruxelles, Belgium
- Professor Isabelle Bekeredjian-Ding, Paul Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Germany
- Professor Daan Crommelin, Department of Pharmaceutics, Utrecht University, the Netherlands
- Professor Maria Beatriz Da Silva Lima, Faculty of Pharmacy,Universidade de Lisboa, Portugal
- Dr Diane Gosselin, Consortium Québécois sur la Découverte du Medicament (CQDM), Canada
- Professor Trevor M Jones, Arix Bioscience plc, UK
- Dr Ángeles Rodriguez Peña, Alberto Sols Biomedical Research Institute, Spain
- Dr Cees Smit, The Netherlands Organisation for Health Research and Development, the Netherlands
- Professor Tanel Tenson, Institute of Technology, University of Tartu, Estonia